Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

“The 340B statute does not permit drug companies to unilaterally withhold discounts from 340B hospitals in exchange for the surrender of purchase data or what are, in essence, pre-payment audits. The ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

An analysis by ING Bank suggests that proposed tariffs could increase the cost of certain cancer treatments by up to $10,000 ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

With blockbuster GLP-1 drugs such as Ozempic, Wegovy from Danish drug maker Novo Nordisk, and Mounjaro from American pharma ...